** Shares of drugmaker Y-mAbs Therapeutics YMAB.O fall 8.5% to $4.75, hitting a near two-year low
** Company forecasts 2025 total revenue to be between $75 million and $90 million, below analysts' estimates of $104.54 million, according to data compiled by LSEG
** YMAB reports Q4 total revenue of $26.5 million, below analysts' estimates of $27.29 million
** In the past 12 months, YMAB has fallen 70%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。